
Ventyx Biosciences, Inc. – NASDAQ:VTYX
Ventyx Biosciences stock price today
Ventyx Biosciences stock price monthly change
Ventyx Biosciences stock price quarterly change
Ventyx Biosciences stock price yearly change
Ventyx Biosciences key metrics
Market Cap | 159.45M |
Enterprise value | 1.44B |
P/E | -15.9 |
EV/Sales | N/A |
EV/EBITDA | -9.60 |
Price/Sales | N/A |
Price/Book | 4.26 |
PEG ratio | -0.23 |
EPS | -3.24 |
Revenue | N/A |
EBITDA | -204.06M |
Income | -192.60M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVentyx Biosciences stock price history
Ventyx Biosciences stock forecast
Ventyx Biosciences financial statements
Jun 2023 | 0 | -53.25M | |
---|---|---|---|
Sep 2023 | 0 | -54.02M | |
Dec 2023 | 1.07M | -46.75M | -4345.07% |
Mar 2024 | 0 | -38.57M |
Mar 2024 | 0 | -38.57M | |
---|---|---|---|
Sep 2025 | 0 | -40.17M | |
Oct 2025 | 0 | -34.83M | |
Dec 2025 | 0 | -34.41M |
Analysts Price target
Financials & Ratios estimates
2024-05-09 | -0.67 | -0.62 |
---|
Jun 2023 | 348763000 | 20.95M | 6.01% |
---|---|---|---|
Sep 2023 | 321701000 | 38.06M | 11.83% |
Dec 2023 | 277693000 | 33.77M | 12.16% |
Mar 2024 | 332078000 | 25.08M | 7.55% |
Jun 2023 | -49.28M | 34.81M | 2.47M |
---|---|---|---|
Sep 2023 | -34.66M | 38.89M | 1.62M |
Dec 2023 | -51.65M | 46.12M | 585K |
Mar 2024 | -47.62M | 41.76M | 96.18M |
Ventyx Biosciences alternative data
Aug 2023 | 76 |
---|---|
Sep 2023 | 91 |
Oct 2023 | 91 |
Nov 2023 | 91 |
Dec 2023 | 99 |
Jan 2024 | 99 |
Feb 2024 | 99 |
Mar 2024 | 79 |
Apr 2024 | 79 |
May 2024 | 79 |
Jun 2024 | 74 |
Jul 2024 | 74 |
Ventyx Biosciences other data
Period | Buy | Sel |
---|---|---|
Apr 2024 | 0 | 9019 |
Nov 2024 | 500000 | 0 |
Dec 2024 | 130000 | 13161 |
Quarter | Transcript |
---|---|
Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
Q2 2023 13 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 14 May 2023 | Q1 2023 Earnings Call Transcript |
Q4 2022 23 Mar 2023 | Q4 2022 Earnings Call Transcript |
-
What's the price of Ventyx Biosciences stock today?
One share of Ventyx Biosciences stock can currently be purchased for approximately $2.58.
-
When is Ventyx Biosciences's next earnings date?
Unfortunately, Ventyx Biosciences's (VTYX) next earnings date is currently unknown.
-
Does Ventyx Biosciences pay dividends?
No, Ventyx Biosciences does not pay dividends.
-
How much money does Ventyx Biosciences make?
Ventyx Biosciences has a market capitalization of 159.45M. Ventyx Biosciences made a loss 192.96M US dollars in net income (profit) last year or -$0.62 on an earnings per share basis.
-
What is Ventyx Biosciences's stock symbol?
Ventyx Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "VTYX".
-
What is Ventyx Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ventyx Biosciences?
Shares of Ventyx Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Ventyx Biosciences have?
As Jul 2024, Ventyx Biosciences employs 74 workers, which is 6% less then previous quarter.
-
When Ventyx Biosciences went public?
Ventyx Biosciences, Inc. is publicly traded company for more then 3 years since IPO on 21 Oct 2021.
-
What is Ventyx Biosciences's official website?
The official website for Ventyx Biosciences is ventyxbio.com.
-
Where are Ventyx Biosciences's headquarters?
Ventyx Biosciences is headquartered at 662 Encinitas Boulevard, Encinitas, CA.
-
How can i contact Ventyx Biosciences?
Ventyx Biosciences's mailing address is 662 Encinitas Boulevard, Encinitas, CA and company can be reached via phone at +7 605934832.
Ventyx Biosciences company profile:

Ventyx Biosciences, Inc.
ventyxbio.comNASDAQ
75
Biotechnology
Healthcare
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Encinitas, CA 92024
CIK: 0001851194
ISIN: US92332V1070
CUSIP: 92332V107